Mackenzie Financial Corp Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Mackenzie Financial Corp decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,105,606 shares of the company's stock after selling 243,789 shares during the period. Mackenzie Financial Corp owned 0.13% of Johnson & Johnson worth $449,133,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of JNJ. MRP Capital Investments LLC lifted its position in shares of Johnson & Johnson by 4.1% in the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock valued at $237,000 after acquiring an additional 65 shares in the last quarter. Syverson Strege & Co increased its stake in Johnson & Johnson by 4.9% in the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock valued at $202,000 after purchasing an additional 65 shares during the last quarter. Werba Rubin Papier Wealth Management increased its stake in Johnson & Johnson by 3.3% in the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock valued at $301,000 after purchasing an additional 66 shares during the last quarter. Denali Advisors LLC increased its stake in Johnson & Johnson by 1.3% in the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock valued at $742,000 after purchasing an additional 67 shares during the last quarter. Finally, Sage Mountain Advisors LLC increased its stake in Johnson & Johnson by 0.5% during the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock worth $2,106,000 after acquiring an additional 67 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent analyst reports. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Argus raised Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Bank of America reduced their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $153.12 on Friday. The stock's fifty day simple moving average is $155.24 and its 200 day simple moving average is $153.72. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a market capitalization of $368.41 billion, a PE ratio of 23.02, a PEG ratio of 2.56 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.40%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is 57.84%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.